| Hosts |
Anastasia Janas and Sam Kessel
|
| Listen | Apple Podcasts Spotify |
| Watch | YouTube |
Summary
Dr. Catherine Stehman-Breen discusses her career journey, from her early interest in medicine to her roles at pharmaceutical companies like Amgen. The highlight is her time as CEO of Chroma Medicine, a biotech focused on epigenetic editing.
Dr Stehman-Breen explains the advantages of epigenetic regulation, and how Chroma initially focused on Hepatitis B. She shares insights on building a biotech company from the ground up, the importance of storytelling, and balancing her career with personal hobbies.
The conversation covers Chroma's recent merger with NVelop Therapeutics, and Dr Stehman-Breen's perspective on the future potential of epigenetic editing to tackle a range of diseases. Overall, it provides an inside look at the challenges and opportunities of leading an innovative biotech startup.
Show Notes
04:14 - Dr. Stehman-Breen discusses her decision to pursue a career in medicine.
05:49 - Dr. Stehman-Breen explains her specialty choice in internal medicine and nephrology.
08:09 - Skills and mindset that prepared Catherine for a career in industry.
13:53 - The critical impact that physicians can have in biotech
19:03 - Overview of epigenetic editing and Chroma Medicine's approach.
28:22 - Early days of building Chroma Medicine from the ground up.
38:22 - Merger with NVelop Therapeutics and future directions.
44:22 - Dr. Stehman-Breen offers advice for entrepreneurs and the value of an Entrepreneur in Residence role.
49:22 - Balancing her demanding career with personal hobbies and interests.
Links
Chroma and Nvelop merger press release
Dr Stehman Breen's LinkedIn
